All In Biotech

Drug Trial Radar · NCT07117474

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Dec 24, 2024

Primary completion

Jun 9, 2026

Study completion Jun 9, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects

Conditions

  • Subjects With Mild Hypertension

Interventions

  • HRS-9563, placeboDrug

    A single subcutaneous injection of HRS-9563 injection or placebo was administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of any adverse eventsTime frame: Evaluation was performed up to Day169

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.